Hemifacial Spasm

Table of Contents

  1. Overview
  2. Pathogenesis
  3. Epidemiology
  4. Clinical Features
  5. Diagnosis
  6. Treatment
  7. Prognosis
  8. Key Research
  9. Connections
  10. Featured Videos

Overview

Hemifacial spasm (HFS) is a chronic neurological disorder characterized by involuntary, unilateral tonic and clonic contractions of the muscles innervated by the facial nerve (cranial nerve VII). Unlike many other movement disorders, HFS is almost always strictly one-sided — it does not cross to the opposite half of the face.

The spasms typically begin around the eye, causing repetitive eyelid twitching or closure (orbicularis oculi muscle), then slowly spread over months to years to involve the cheek, the corner of the mouth, and ultimately the platysma in the neck. The combination of eye and mouth involvement on the same side is a hallmark that helps clinicians distinguish HFS from other facial movement disorders.

In most cases the underlying cause is a blood vessel pressing on the facial nerve at the point where it exits the brainstem — a location called the root exit zone (REZ). Because the condition is caused by a structural abnormality that is surgically correctable, HFS occupies a unique position in neurology: it is one of the few movement disorders that can be permanently cured with an operation.

Back to Table of Contents

Pathogenesis

The dominant mechanism behind HFS is neurovascular compression at the root exit zone (REZ) of the facial nerve — the short segment of nerve just as it leaves the brainstem where the myelin sheath transitions from central (oligodendrocyte-derived) to peripheral (Schwann cell-derived). This transition zone is especially vulnerable to mechanical injury.

In roughly 75–80% of cases the offending vessel is the posterior inferior cerebellar artery (PICA). The anterior inferior cerebellar artery (AICA) and vertebral artery account for most remaining cases. The vessel pulsates against the nerve with every heartbeat, causing focal demyelination over time.

Demyelination at the REZ leads to ephaptic transmission — electrical cross-talk between neighboring, normally insulated nerve fibers. When one fiber fires, the signal "jumps" to adjacent fibers, triggering synchronous, abnormal discharges across multiple motor branches simultaneously. This explains the defining clinical hallmark: a contraction in one muscle group triggering simultaneous contraction elsewhere on the same side of the face.

A particularly useful diagnostic sign is the Babinski-II sign (sometimes called Babinski's "other" sign or the orbicularis sign): when the patient closes the eye, the corner of the mouth contracts involuntarily on the same side. This synkinesis pattern — eye closure driving mouth movement — reflects ephaptic transmission and is considered pathognomonic of HFS. Normal people cannot reproduce this pattern voluntarily.

Synkinesis more broadly refers to any involuntary co-movement — for example, the eye narrowing when the patient smiles. It is not present in benign essential blepharospasm (which is bilateral and lacks lower-face spread) or in peripheral facial palsy synkinesis (which appears after nerve regeneration, not at onset).

Secondary HFS accounts for approximately 2–3% of cases and arises from structural lesions compressing CN VII: cerebellopontine angle tumors (acoustic neuroma, meningioma, epidermoid cyst), arteriovenous malformations (AVMs), or, rarely, demyelinating plaques in multiple sclerosis. Because the presentation is identical to the primary form, neuroimaging is mandatory in every patient before attributing the diagnosis to idiopathic neurovascular compression.

Back to Table of Contents

Epidemiology

Hemifacial spasm has an estimated prevalence of approximately 7.4 per 100,000 population in Western countries, making it a relatively uncommon but not rare disorder. Incidence estimates range from 0.74 to 0.81 per 100,000 person-years.

Sex distribution: Women are affected roughly twice as often as men. The reason for this sex difference is not fully understood; anatomical differences in posterior fossa dimensions have been proposed.

Age of onset: HFS most commonly begins between the ages of 40 and 60 years, with a peak in the fifth decade. Onset before age 40 is less common but well-documented; very early-onset cases (under age 30) warrant particular attention to secondary causes such as AVMs or demyelinating disease.

Laterality: The left side is affected slightly more often than the right in most series, possibly because the left vertebral artery is typically more dominant, making neurovascular contact at the left REZ more likely.

Family history is positive in approximately 1–2% of cases. Familial HFS tends to present at a younger age and may reflect shared vascular anatomy or connective tissue variation rather than a specific genetic mutation.

Without treatment HFS is a chronic, slowly progressive condition. Episodes become more frequent and severe over years. Spontaneous remission is rare — estimated at less than 10% — and temporary remissions are often followed by recurrence.

Back to Table of Contents

Clinical Features

The clinical presentation of hemifacial spasm is distinctive enough that an experienced clinician can usually make the diagnosis on history and examination alone, before any investigations are ordered.

Onset and Progression

HFS almost invariably begins with intermittent, fine twitching of the lower eyelid — what patients often describe as "my eye twitching." At this stage the condition is frequently misattributed to fatigue, stress, or caffeine excess. Over months to years the spasms involve the entire orbicularis oculi muscle, causing forceful eye closure. They then spread to the zygomaticus major (cheek), the orbicularis oris (lip), and eventually the platysma in some patients.

Character of the Movements

The spasms have both clonic (rhythmic, repetitive jerking) and tonic (sustained contraction, causing the eye to be held shut for seconds) components. The combination distinguishes HFS from pure blepharospasm, which is bilateral and predominantly tonic, and from myokymia, which is a fine undulating ripple without the tonic component.

Aggravating Factors

Spasms are characteristically worsened by stress, fatigue, anxiety, and voluntary facial movement (e.g., talking, smiling, chewing). Interestingly, unlike tremors, they do not reliably diminish with distraction or at rest, and they persist during sleep — a feature that sets HFS apart from many psychogenic or functional movement disorders.

Associated Symptoms

Back to Table of Contents

Diagnosis

Diagnosis of hemifacial spasm is primarily clinical, supported by neuroimaging and electrophysiologic studies.

Clinical Diagnosis

The key features that confirm the diagnosis are: (1) unilateral distribution strictly confined to muscles supplied by CN VII; (2) the presence of both tonic and clonic components; (3) the Babinski-II sign (orbicularis oculi contraction triggering ipsilateral orbicularis oris contraction); and (4) persistence during sleep. The differential diagnosis includes essential blepharospasm (bilateral, no lower-face spread), focal motor seizures (more rapid, often involving the limb, EEG abnormality), hemimastication spasm (CN V territory, jaw deviation), and facial myokymia (rippling wave, often associated with MS or brainstem glioma).

Neuroimaging

MRI of the brain with dedicated posterior fossa sequences is mandatory in all patients. The preferred protocol includes high-resolution constructive interference in steady state (CISS) or fast imaging employing steady-state acquisition (FIESTA) sequences, which provide excellent contrast between CSF and neural/vascular structures. These sequences can demonstrate the offending vessel in contact with the facial nerve at the REZ. Contrast-enhanced imaging helps exclude secondary causes such as tumors or AVMs. Approximately 80–90% of patients with HFS will show neurovascular contact on dedicated MRI sequences, though incidental contact without clinical significance also occurs in normal subjects.

Electrophysiology

Electromyography (EMG) and the lateral spread response are the most useful confirmatory tests. The lateral spread response involves stimulating one branch of CN VII (e.g., the marginal mandibular branch) and recording an abnormal compound muscle action potential in a muscle supplied by a different branch (e.g., the orbicularis oculi). This lateral spread is present in virtually all patients with HFS and is absent in healthy controls, confirming ephaptic transmission at the REZ. The test also has intraoperative utility: disappearance of the lateral spread response during microvascular decompression surgery correlates with surgical success.

Back to Table of Contents

Treatment

Three main treatment strategies exist for hemifacial spasm: botulinum toxin injections (the most widely used first-line approach), pharmacological therapy, and microvascular decompression surgery (the only curative option).

Botulinum Toxin Injections (First-Line)

Botulinum toxin type A (onabotulinumtoxinA, Botox; abobotulinumtoxinA, Dysport) is considered the first-line treatment for the majority of patients. The toxin is injected directly into the affected facial muscles — typically the orbicularis oculi, zygomaticus, and orbicularis oris — in small doses using a fine needle. It works by blocking acetylcholine release at the neuromuscular junction, producing temporary, localized muscle weakness that suppresses the spasms without affecting the underlying neurological cause.

The effects typically last 3–4 months, requiring repeat injections. Response rates are excellent: approximately 90% of patients achieve meaningful reduction in spasm severity. Side effects are generally mild and transient, including drooping of the eyelid (ptosis), tearing, local bruising, and mild facial asymmetry. With experienced injectors the complication rate is low.

Botulinum toxin does not cure HFS — the underlying neurovascular compression persists — but it provides reliable, predictable symptomatic control. Most patients choose to continue indefinitely with injections, particularly older patients or those for whom surgery carries elevated risk.

Pharmacological Therapy

Carbamazepine (an anticonvulsant that stabilizes sodium channels) provides modest symptomatic relief in some patients and may be useful as bridging therapy while awaiting botulinum toxin appointments or surgical evaluation. Response rates are substantially lower than with botulinum toxin, and side effects (sedation, hyponatremia, rash, drug interactions) limit its use. Gabapentin, clonazepam, and baclofen have also been used with limited evidence.

Microvascular Decompression (MVD)

Microvascular decompression (MVD), also known as the Jannetta procedure after its pioneer Peter Jannetta, is the only treatment that addresses the root cause of HFS. The operation involves a retrosigmoid craniotomy (a small opening behind the ear), identification of the offending vessel at the facial nerve REZ under the operating microscope, and placement of a small Teflon pledget between the vessel and the nerve to relieve the compression.

MVD achieves immediate or early cure in approximately 90–95% of patients, with long-term recurrence rates of 10–15% over 10 years. It is the preferred option for younger patients (who would otherwise face decades of repeat injections), for those who prefer a definitive cure, and for those with incomplete botulinum toxin response.

Risks of MVD are real and must be discussed candidly: sensorineural hearing loss (1–3%; intraoperative brainstem auditory evoked response [BAER] monitoring reduces but does not eliminate this risk), facial nerve palsy (1–2%), CSF leak, infection, and stroke. Mortality is less than 0.5% in experienced centers. The operation should be performed by neurosurgeons who specialize in posterior fossa microvascular surgery, as outcomes are strongly volume-dependent.

Back to Table of Contents

Prognosis

Without treatment, hemifacial spasm is a progressive, lifelong condition. Spontaneous remission occurs in fewer than 10% of patients and is often temporary. Over years, spasms become more frequent, more forceful, and involve a wider area of the face. Sustained tonic spasm can impair vision in the affected eye and eventually cause functional visual loss if the eye remains involuntarily closed for prolonged periods.

With botulinum toxin, most patients achieve excellent quality of life with 3- to 4-monthly injections. The effectiveness of injections tends to be maintained over many years; tolerance (a primary reduction in efficacy) is uncommon with botulinum toxin type A used at appropriate doses. Secondary non-response due to neutralizing antibody formation is rare but possible, particularly if high doses are used at short intervals.

With microvascular decompression, the probability of being spasm-free at one year is approximately 90%, and approximately 80% remain spasm-free at 10 years. A proportion of patients experience a delayed cure — spasms resolve gradually over weeks to months after the procedure — which is thought to reflect the time required for damaged myelin to heal after the compressing vessel is moved away. Patients should be counseled not to judge surgical success in the immediate postoperative period.

The choice between botulinum toxin and MVD is individualized. Age, general health, degree of disability, patient preference, and access to experienced surgical centers all factor into shared decision-making. Neither approach is universally superior — each has a defined and valuable role.

Back to Table of Contents

Key Research

  1. Jannetta PJ et al. Etiology and definitive microsurgical treatment of hemifacial spasm. Operative techniques and results in 47 patients. J Neurosurg. 1977. PMID: 1045349
  2. Wang A, Jankovic J. Hemifacial spasm: clinical findings and treatment. Muscle Nerve. 1998. PMID: 9589465
  3. Rosenstengel C et al. Hemifacial spasm: conservative and surgical treatment options. Dtsch Arztebl Int. 2012. PMID: 23526548
  4. Kenney C et al. Long-term treatment with botulinum toxin in hemifacial spasm. Mov Disord. 2005. PMID: 15991526
  5. Miller LE, Miller VM. Safety and effectiveness of microvascular decompression for treatment of hemifacial spasm: a systematic review. Br J Neurosurg. 2012. PMID: 22391295
  6. Auger RG, Whisnant JP. Hemifacial spasm in Rochester and Olmsted County, Minnesota, 1960 to 1984. Arch Neurol. 1990. PMID: 2173421
  7. Sindou M et al. Microvascular decompression for hemifacial spasm: outcomes on 400 consecutive patients with emphasis on late results. Acta Neurochir (Wien). 2009. PMID: 19301419
  8. Illingworth RD et al. Microvascular decompression for hemifacial spasm: a long-term follow-up of 176 cases. J Neurosurg. 1996. PMID: 12431279
  9. Tan EK, Chan LL. Young onset hemifacial spasm. Acta Neurol Scand. 2006. PMID: 16477566
  10. Bhidayasiri R et al. Epidemiology of hemifacial spasm. J Neurol. 2011. PMID: 21294802
  11. Patel A et al. Hemifacial spasm: a brief review and a comprehensive approach to treating. Semin Plast Surg. 2013. PMID: 23557769
  12. Defazio G et al. Prevalence and risk factors for familial hemifacial spasm: a multicenter investigation. Arch Neurol. 2006. PMID: 16832099

Back to Table of Contents

Connections

Back to Table of Contents